Gatifloxacin is a fourth-generation 8-methoxy performance liquid chromatography (HPLC) and fluoroquinolone derivative (1-cyclopropyl-6-fluoro-8-microbiological assay methods were reported for the methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroestimation of gatifloxacin in biological fluids such as quinoline-3-carboxylic acid) with a broad spectrum of plasma, serum, and urine. [4] [5] [6] [7] Reported HPLC methods activity encompassing gram-positive and gram-negative used different detectors like electron-spray tandem mass pathogens, including S. epidermidis, S. aureus, S.
spectrometry, ultraviolet and fluorescence. Overholser et pneumoniae, S. pyogenes, H. influenzae, E. coli, B. al., have developed and validated a HPLC method for the cereus, N. gonorrhoeae, and P. mirabilis. Additionally, estimation of gatifloxacin in human serum and urine gatifloxacin is highly active against atypical pathogens, samples. 8 But, chromatographic techniques demand a lot such as Mycoplasma, Legionella, and Chlamydia species, of time and expertise in their operation with higher cost. as well as the anaerobic organism P. acnes. [1] [2] More Thus there is a need to develop a simple, rapid, and cost favorable pharmacokinetic properties of gatifloxacin are effective method with low estimation range for routine analysis.
The objective of the present study was to develop simple, sensitive, precise, accurate, and economic analytical method with better detection range for the estimation of gatifloxacin in bulk, and in pharmaceutical formulations, and for in vitro dissolution studies of oral and ophthalmic formulations. Analytical method was developed in 10 mM hydrochloric acid (pH 2.0). In the selected medium the relative fluorescence intensity was measured at λ of 292 nm and λ of 482 nm. No www.ijpsonline.com and USP requirements. 9, 10 Suitable statistical tests were performed on validation data.
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MATERIALS AND METHODS
Gatifloxacin was obtained as a gift sample from Venkar Chemicals Pvt. Ltd., India. Formulations containing gatifloxacin: Gaity-200 tablets, labeled to contain 200 mg of gatifloxacin per tablet (Dr. Reddy's Laboratories Ltd., India), Gaity-400 tablets, labeled to contain 400 mg of gatifloxacin per tablet (Dr. Reddy's Laboratories Ltd., prepared from the stock solution and analysed. Least India) and Gatilox concentrated injection, labeled to square regression analysis was done for the obtained contain gatifloxacin 10 mg/ml (Solares, Sun Pharma, India) data. ANOVA test (one-way) was performed based on the were collected. Gatifloxacin ophthalmic solution of 0.3 relative fluorescence intensity values observed for each %w/v strength was prepared in the laboratory using pure drug concentration during the replicate measurement phosphate buffer saline (pH 7.4) as vehicle, under aseptic of the standard solutions. conditions. Apart from common excipients Gaity-200 and Gaity-400 tablets contain excipients like iron oxide yellow Analytical validation: and titanium oxide. Gatilox concentrated injection contains Gatifloxacin solutions (100 ng/ml) were prepared in the excipients like dextrose and water for injection.
selected medium with and without common excipients Gatifloxacin ophthalmic solution contains 0.01 %w/v of (lactose, starch, methyl benzalkonium chloride (preservative) in aqueous vehicle.
hydroxypropylmethylcellulose, microcrystalline-cellulose, All other chemicals and reagents used were of analytical dextrose, iron oxide yellow, titanium oxide, magnesium grade. All fluorescence measurements were done on a stearate, talc and benzalkonium chloride) separately. All spectrofluorimeter (Jasco FP777, Japan) loaded with inthe solutions were scanned (400 nm/min) for emission built software and equipped with a 150 W Xenon lamp, spectrum by fixing the λ exc at 292 nm and checked for using 10 mm quartz cells. Measurement parameters were: the change in emission spectrum. In a separate study excitation band width -3 nm, emission band width -5 nm, drug concentration of 150 ng/ml was prepared photo-multiplier tube response -high, slit width -0.5 nm, independently from pure drug stock and formulation = 292 ± 1 nm and λ em = 482 ± 1 nm.
sample stock in selected medium and analysed (n = 5). Paired t-test at 95% level of significance was performed Method development:
to compare the means of relative fluorescence intensity. Different pH media alone and in combination with different organic solvents, in various proportions, were As a part of determining accuracy of the proposed tried. For selection of media the criteria employed was method, different levels of drug concentrations (LQCsensitivity of the method, ease of sample preparation, 25 ng/ml, MQC -75 ng/ml, and HQC -150 ng/ml) were solubility of the drug, cost and applicability of the method prepared independently from stock solution and analysed cellulose, λ exc for various purposes. Primary stock solution of 200 µg/ml of gatifloxacin was prepared in 10 mM hydrochloric acid (pH 2.0). Using aliquot of primary stock solution, secondary stock solution of 1 µg/ml was prepared in 10 mM hydrochloric acid. For preparation of different concentrations, aliquots of secondary stock solution were transferred into series of 10 ml standard flasks and volume was made with 10 mM hydrochloric acid. Five different concentrations (20, 60, 100, 140, and 160 ng/ml) of gatifloxacin were prepared for calibration curve. Relative fluorescence intensity was measured at λ exc of 292 nm and λ em of 482 nm against blank (Table 1) . To establish linearity of the proposed method, six separate series of solutions of the drug in selected medium were (n = 6). Accuracy was assessed as the percentage relative error and mean percentage recovery (Table 2) . To give additional support to accuracy of the developed assay method, standard addition method was done. In this study, different concentrations of pure drug (20, 40, 60, 80, and 100 ng/ml) were added to a known pre-analysed formulation sample (drug concentration of 50.3 ng/ml) and the total concentration was determined using the proposed method (n = 3). The percent recovery of the added pure drug was calculated as, % recovery = [(CvCu)/Ca] × 100, where Cv is the total drug concentration measured after standard addition; Cu, drug concentration in the formulation; Ca, drug concentration added to formulation. www.ijpsonline.com Repeatability was determined by using different levels of solution was diluted suitably to prepare a 200 µg/ml drug concentrations (as mentioned in accuracy), prepared concentration. This primary stock solution was filtered from independent stock solution and analysed (n = 6) through Whatman filter paper number 40 and the filtrate ( Table 3) . Inter-and intra-day variation and analyst was further diluted suitably to prepare a secondary stock variation was studied to determine intermediate precision solution of 1 µg/ml concentration. Aliquot of the of the proposed method. Different levels of drug secondary stock solution was diluted to a concentration of concentrations in triplicates were prepared two different 50 ng/ml and the samples were analyzed using proposed times in a day and studied for intra-day variation. Same method. Same procedure was followed for the tablets of protocol was followed for three different days to study strength 200 and 400 mg. inter-day variation (n = 18). Different analysts prepared different solutions on different days. The relative Aliquot of gatifloxacin injection (10 mg/ml strength) standard deviation (in %) of the predicted concentrations equivalent to 5 mg of drug was taken and diluted in the from the regression equation was taken as precision selected medium to get a 200 µg/ml concentration primary stock. Rest of the sample preparation was same as used for tablets and samples were analyzed. The detection limit (DL) and quantitation limit (QL) of gatifloxacin by the proposed method was determined Aliquot of gatifloxacin ophthalmic solution (0.3% w/v using calibration standards. DL and QL were calculated strength) equivalent to 300 µg of drug was taken and as 3.3 σ/S and 10 σ/S respectively, where S is the slope diluted in the selected medium to get a 3 µg/ml of the calibration curve and σ is the standard deviation concentration primary stock. Aliquot of the primary stock of y-intercept of regression equation. 9 Robustness of the solution was diluted to a concentration of 150 ng/ml and proposed method was determined by (a) changing pH of the samples were analysed. Five replicates were the media by ±0.1 units and (b) stability of drug in the prepared in all the cases. selected medium at room temperature for 8 h. Three different concentrations (LQC, MQC and HQC) were
RESULTS AND DISCUSSION
prepared in different pH media and mean percentage recovery was determined.
For media optimization various aqueous media like 10 mM hydrochloric acid, acetate buffers (pH 3.6-5.8), phosphate Estimation from formulations: buffers (pH 5.8-8.0) and 100 mM sodium hydroxide were (Table 3) .
Twenty tablets were weighed and pulverized. Amount of the powder equivalent to 5 mg of gatifloxacin was taken and extracted with selected medium for 30 min. The investigated. Addition of acetonitrile/methanol in various proportions with various aqueous media did not improve the sensitivity of the method. Sensitivity was found to be maximum in 10 mM hydrochloric acid medium. The final decision of using 10 mM hydrochloric acid (pH 2.0) as a medium was based on certain criteria like; sensitivity of the method, cost, ease of preparation and applicability of the method to different purposes. The excitation and emission spectra of gatifloxacin in 10 mM hydrochloric acid are shown in fig. 1 .
Different concentrations and their relative fluorescence intensities were shown in the Table 1 . At all the concentration levels the standard deviation was low and the relative standard deviation (RSD) did not exceed 2.5%. The predicted concentrations were nearly matching with the nominal concentration. In selected medium the linearity range was found to be 20-160 ng/ml. According to linear regression analysis, the slope (± standard error) and intercept (± standard error) were found to be 36.05 (±8.38 × 10 -2
) and 12.60 (± 8.641), respectively. These mean values were found to be within the 95% confidence limits (confidence limits of slope: 35.88-36.22; confidence limits of intercept: from -4.451 to 29.64). Goodness of fit of regression equation was supported by same concentration of pure drug sample and formulation sample were compared by paired t-test (at 8 df), the calculated t-value (0.244) was found to be less than that of the critical t-value (2.306), indicating that statistically there was no significant difference between mean relative fluorescence intensities. The interference of excipients was insignificant in the estimation of drug. Therefore proposed method was specific and selective for the drug. 9.98 ± 0.07 99.83 ± 0.67 Mean ± SD (mg/ml) Ophthalmic solution (0.3% w/v = 3 mg/ml) a 3.00 ± 0.02 99.89 ± 0.67 Mean ± SD (mg/ml) rapid, accurate, precise, and inexpensive and can be used for routine analysis of gatifloxacin in bulk, pharmaceutical formulations and dissolution studies of oral and ophthalmic formulations. Detection limit of the proposed method is lower than the reported UVSpectrophotometric method 3 and HPLC method. 8 The sample recoveries in all formulations were in good agreement with their respective label claims, indicating non-interference of excipients in the estimation. The usage of any organic solvent for extraction of gatifloxacin from the formulations is not required.
a Formulation was prepared in laboratory. Each value is average of five separate determinations
